Q2 FY2026 EarningsQ2 FY2026 results significantly exceeded consensus estimates across top and bottom lines: revenue reached $29.1M vs. $26.3M expected, while Diluted EPS (GAAP) of $0.07 beat the expected -$0.09 loss. Performance was driven by a 30% YoY volume surge in HEPZATO procedures and expanded gross margins of 90%. Management raised FY2026 revenue guidance to $104M-$108M, signaling robust demand for interventional oncology solutions.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Delcath(DCTH) the Revenue is 29.13 M (+20.6%), Beat estimate;the EBIT is 2.395 M (-7.53%), Beat estimate;the EPS is 0.07 (+0%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B20.60%
0.03B8.71%
+0.00B11.89%
EBITExceed expectations
0.00B7.53%
-0.00B257.81%
+0.01B250.28%
EPSExceed expectations
0.07--
-0.09228.57%
+0.1600228.57%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf